未登录

L

Lars Viktrup

ucl medical school

H指数:45

被引数:6,414

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Effectiveness of galcanezumab versus topiramate, amitriptyline, and other select traditional oral migraine preventives with evidence of efficacy: 3-Month results from the TRIUMPH study

与托吡酯、阿米替林及其他具有疗效证据的选择性传统口服偏头痛预防药物相比，加卡纳zumab的有效性：TRIUMPH研究3个月结果

IF4

2026-04-010

OAAI

Treatment effectiveness of galcanezumab versus traditional oral migraine preventive medications at 3 months: Results from the TRIUMPH study

与传统的口服偏头痛预防药物相比，galcanezumab在3个月时的治疗效果：TRIUMPH研究的结果

IF0

2025-09-290

PREAI

Monthly Headaches and Severity in Patients on Galcanezumab or Traditional Preventive Migraine Medication: A 24-Month Claims and Electronic Health Records Study

NEUROLOGY AND THERAPY

IF4.8

2025-04-010

OAAI

Association of Pain During Exercise With Exercise-Induced Hypoalgesia in People With Knee Osteoarthritis

ARTHRITIS CARE & RESEARCH

IF3.3

2025-04-010

PRE

Interictal burden in migraine patients at the outset of CGRP monoclonal antibody prevention

JOURNAL OF HEADACHE AND PAIN

IF7.9

2024-12-180

OAAI

Healthcare Utilization, Costs, and Treatment Discontinuation in Adults with Episodic Migraine Initiating Galcanezumab Versus Rimegepant: A US Retrospective Claims Analysis

ADVANCES IN THERAPY

IF4

2024-12-160

OAAI

A 3-year follow-up study of outcomes associated with patterns of traditional acute and preventive migraine treatment: An administrative claims-based cohort study in the United States

IF4

2024-06-190

OAAI

Characterization of adverse joint outcomes in patients with osteoarthritis treated with subcutaneous tanezumab

OSTEOARTHRITIS AND CARTILAGE

IF9

2023-12-015

OA

Stigmatizing attitudes about migraine by people without migraine: Results of the overcome (US) study

JOURNAL OF THE NEUROLOGICAL SCIENCES

IF3.2

2023-12-010

PRE

Beyond migraine headache day reduction: Clinically meaningful improvement in disability (MIDAS score) in the absence of greater than 50% reductions in monthly migraine days with galcanezumab

IF8.5

2023-04-250

PRE

What trade-offs are patients willing to make when selecting between novel preventive treatments for migraine? Evidence from a Discrete Choice Experiment

IF8.5

2023-04-250

PRE

Opioids for Osteoarthritis: Cross-Sectional Survey of Patient Perspectives and Satisfaction

JOURNAL OF CLINICAL MEDICINE

IF2.9

2023-04-061

OAAI

Reliability of Wearable Sensors for Assessing Gait and Chair Stand Function at Home in People With Knee Osteoarthritis

ARTHRITIS CARE & RESEARCH

IF3.3

2023-03-075

PRE

Predicting Treatment Responses in Patients With Osteoarthritis: Results From Two Phase III Tanezumab Randomized Clinical Trials

预测骨关节炎患者的治疗反应: 两项III期Tanezumab随机临床试验的结果

CLINICAL PHARMACOLOGY & THERAPEUTICS

IF5.5

2023-01-314

OAAI

Opioid Prescribing for Osteoarthritis: Cross-Sectional Survey among Primary Care Physicians, Rheumatologists, and Orthopaedic Surgeons

JOURNAL OF CLINICAL MEDICINE

IF2.9

2023-01-110

OAAI

Characterizing 16-Week Responder Profiles Using Group-Based Trajectory Modeling in Over 4300 Clinical Trial Participants Receiving Pharmaceutical Treatment for Moderate to Severe Osteoarthritis

ADVANCES IN THERAPY

IF4

2022-08-120

PRE

General Safety and Tolerability of Subcutaneous Tanezumab for Osteoarthritis: A Pooled Analysis of Three Randomized, Placebo-Controlled Trials

ARTHRITIS CARE & RESEARCH

IF3.3

2022-03-258

OAAI

WOMAC Meaningful Within-patient Change: Results From 3 Studies of Tanezumab in Patients With Moderate-to-severe Osteoarthritis of the Hip or Knee

JOURNAL OF RHEUMATOLOGY

IF3.4

2022-03-0115

OA

Neurological safety of subcutaneous tanezumab versus NSAID in patients with osteoarthritis

JOURNAL OF THE NEUROLOGICAL SCIENCES

IF3.2

2022-03-014

OAAI

Exploring patient preference heterogeneity for pharmacological treatments for chronic pain: A latent class analysis

EUROPEAN JOURNAL OF PAIN

IF3.4

2022-01-087

OA